A former senior player from Gilead Sciences has joined global biopharma Terns Pharmaceuticals as Chief Medical Officer bringing over two decades of clinical medicine and drug development experience.
At Gilead, Erin Quirk served as Vice President of Clinical Research where she oversaw all phases of the company’s clinical development for HIV treatment, prevention and cure franchise.
Previously, she was Director of Clinical Research at Merck where she advanced clinical trials for the company’s investigational HIV vaccine products and oversaw the clinical development of small molecules for hepatitis C virus infection.
Weidong Zhong, President and CEO of Terns, said: “Erin is a highly accomplished clinician with an extensive track record in developing and registering new treatments for infectious diseases and liver diseases.
“Her expertise will be invaluable as we advance our portfolio of NASH drugs, including TERN-101, TERN-201, and future pipeline candidates, through the clinic.”